Metropolis Healthcare reported a robust start to FY2027 with 17% year-on-year revenue growth in Q1, exceeding its own guidance. The company saw healthy expansion in both patient and test volumes, driving improved margins to 25.2%. The positive performance was underpinned by strong growth in both B2C and B2B segments, and the ongoing integration of recent acquisitions.
Metropolis Healthcare Reports Strong Q1 FY2027 Performance
Metropolis Healthcare Limited announced a strong performance for the first quarter of FY2027, with revenue growing by 17% year-on-year to INR 450 crores. This figure surpassed the company’s stated guidance, driven primarily by robust volume growth. The company also reported a healthy expansion in its EBITDA margin, which reached 25.2%, an increase of 210 basis points year-on-year.
Key Financial Highlights
The Q1 FY2027 results showcased broad-based growth across all business segments and geographies. Patient volumes increased by 10%, and test volumes by 11% year-on-year. The B2C segment grew by 18%, while the B2B segment saw a growth of 15%. Profit After Tax (PAT) stood at INR 57 crores, marking a 26% year-on-year increase, with PAT margin expanding by 90 basis points to 12.6%.
Growth Drivers and Strategic Initiatives
The company attributed its strong performance to several factors, including: network expansion, particularly in Tier-2 and Tier-3 cities, with plans to add 400-500 centers in these regions this year; strengthening of its Specialty Diagnostics portfolio and TruHealth offerings; and continued investments in technology and digital transformation. The integration of acquired businesses, such as Core Diagnostics, is progressing well and contributing to the growth.
Outlook and Margin Guidance
Metropolis Healthcare reiterated its revenue growth outlook of 14%-15% for the full year, expected to be driven by volume growth. The company also anticipates an improvement of 100-150 basis points on EBITDA during the current financial year, aiming for an EBITDA margin of 27%-28% in the medium term. The company’s strategic priorities for FY2027 include accelerating network expansion, strengthening Specialty Diagnostics, enhancing the TruHealth portfolio, leveraging technology, and pursuing disciplined inorganic growth.
Acquisition Integration Progress
The integration of recent acquisitions, including Core Diagnostics, is on track. The company highlighted that the acquisition of Core Diagnostics has doubled its genomics portfolio and strengthened its presence in North India, now contributing 18% of overall revenue. The focus is shifting from integration to growth, leveraging the pan-India network to expand Core’s Super Specialty capabilities.
Source: BSE
